热门资讯> 正文
Orthoatrics 25财年收入为2.361亿美元
2026-01-12 20:50
- OrthoPediatrics (KIDS) on Monday said posted record preliminary unaudited full year 2025 net revenue of $236.1 million, representing continued growth compared to $204.7 million in 2024 of 15%.
- Preliminary full year domestic net revenue is expected to be $186.2 million, representing 16% annual growth and international net revenue is expected to be $49.9 million, representing 15% annual growth.
- The company generated preliminary unaudited fourth quarter 2025 net revenue of $61.3 million, representing 16% growth compared to $52.7 million in the fourth quarter of 2024.
- Preliminary domestic fourth quarter net revenue is expected to be $48.4 million, representing 13% growth compared to the prior year period, and international net revenue is expected to be $12.9 million, representing 32% growth compared to the prior year period.
- Consensus for FY25 amd Q4 revenues are $233.99M and $59.28M.
- For Q4, it generated about $6M - $7M free cash flow.
- 2026 Financial Guidance:OrthoPediatrics projects 2026 revenue to be in the range of $262 million to $266 million, representing 11% to 13% growth compared to full year 2025 preliminary unaudited net revenue. The company also expects approximately $10 million annual set deployment and expects to generate approximately $25 million Adjusted EBITDA in 2026.
- Source: Press Release
More on OrthoPediatrics
- OrthoPediatrics Corp. (KIDS) Q3 2025 Earnings Call Transcript
- OrthoPediatrics outlines path to 12% baseline growth and free cash flow breakeven by 2026 amid clinic expansion and strong T&D momentum
- Seeking Alpha’s Quant Rating on OrthoPediatrics
- Historical earnings data for OrthoPediatrics
- Financial information for OrthoPediatrics
风险及免责提示:以上内容仅代表作者的个人立场和观点,不代表华盛的任何立场,华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前,应结合自身情况,考虑投资产品的风险。必要时,请咨询专业投资顾问的意见。华盛不提供任何投资建议,对此亦不做任何承诺和保证。